4.4 Article

Combination gene therapy with PTEN and EGFR siRNA suppresses U251 malignant glioma cell growth in vitro and in vivo

Journal

MEDICAL ONCOLOGY
Volume 27, Issue 3, Pages 843-852

Publisher

HUMANA PRESS INC
DOI: 10.1007/s12032-009-9295-8

Keywords

Glioma; PTEN; EGFR; Small interference RNA; Combinatory gene therapy

Categories

Funding

  1. Program for New Century Excellent Talents in University [NCET-07-0615]
  2. Tianjin Science and Technology Committee [09JCZDJC17600]

Ask authors/readers for more resources

The over-expression/amplification of the epidermal growth factor receptor (EGFR) gene and mutation/deletion of tumor suppressor PTEN gene are main genetic changes identified in glioblastomas. These two genetic changes play a critical role in the formation of many malignant tumors and have been shown to be the important therapeutic targets. In this study, we used an expression plasmid that expresses small hairpin RNA-targeting sequences of human EGFR and wild-type PTEN cDNA to examine the growth inhibitive effects in U251 glioma cells. It was found that down-regulation of EGFR expression and up-regulation of PTEN expression resulted in the suppression of cell proliferation, arrest of cell cycle, reduction in cell invasion and promotion of cell apoptosis in vitro. In addition, the growth of the subcutaneous U251 glioma in the nude mice treated with expression plasmid was significantly inhibited. Our results demonstrated that the expression plasmid could exert proliferation and invasion inhibition effects on U251 cells in vitro and in vivo. It suggested that combinatory gene therapy targeting EGFR and PTEN would be a new strategy in gene therapy of glioblastoma.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biotechnology & Applied Microbiology

Increased Microglial Exosomal miR-124-3p Alleviates Neurodegeneration and Improves Cognitive Outcome after rmTBI

Xintong Ge, Mengtian Guo, Tianpeng Hu, Wenzhu Li, Shan Huang, Zhenyu Yin, Ying Li, Fanglian Chen, Luoyun Zhu, Chunsheng Kang, Rongcai Jiang, Ping Lei, Jianning Zhang

MOLECULAR THERAPY (2020)

Article Cell Biology

Downregulation of miRNA-146a-5p promotes malignant transformation of mesenchymal stromal/stem cells by glioma stem-like cells

Xingliang Dai, Yunfei Wang, Xuchen Dong, Minfeng Sheng, Haiyang Wang, Jia Shi, Yujing Sheng, Liang Liu, Qianqian Jiang, Yanming Chen, Bingshan Wu, Xuejun Yang, Hongwei Cheng, Chunsheng Kang, Jun Dong

AGING-US (2020)

Review Immunology

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma

Na Zhang, Li Wei, Meng Ye, Chunsheng Kang, Hua You

FRONTIERS IN IMMUNOLOGY (2020)

Article Biochemistry & Molecular Biology

FUNDC1-dependent mitophagy induced by tPA protects neurons against cerebral ischemia-reperfusion injury

Ying Cai, Eryan Yang, Xiuhua Yao, Xuebin Zhang, Qixue Wang, Yunfei Wang, Ji Liu, Weijia Fan, Kaikai Yi, Chunsheng Kang, Jialing Wu

Summary: tPA exerts neuroprotective effects by increasing phosphorylation of AMPK and expression of FUNDC1, thereby inhibiting apoptosis and improving mitochondrial function.

REDOX BIOLOGY (2021)

Review Oncology

Premature MicroRNA-Based Therapeutic: A One-Two Punch against Cancers

Luyue Chen, Kai Huang, Kaikai Yi, Yanlin Huang, Xinhua Tian, Chunsheng Kang

CANCERS (2020)

Review Oncology

Clinical practice guidelines for the management of adult diffuse gliomas

Tao Jiang, Do-Hyun Nam, Zvi Ram, Wai-Sang Poon, Jiguang Wang, Damdindorj Boldbaatar, Ying Mao, Wenbin Ma, Qing Mao, Yongping You, Chuanlu Jiang, Xuejun Yang, Chunsheng Kang, Xiaoguang Qiu, Wenbin Li, Shaowu Li, Ling Chen, Xuejun Li, Zhixiong Liu, Weimin Wang, Hongmin Bai, Yu Yao, Shouwei Li, Anhua Wu, Ke Sai, Guilin Li, Kun Yao, Xinting Wei, Xianzhi Liu, Zhiwen Zhang, Yiwu Dai, Shengqing Lv, Liang Wang, Zhixiong Lin, Jun Dong, Guozheng Xu, Xiaodong Ma, Wei Zhang, Chuanbao Zhang, Baoshi Chen, Gan You, Yongzhi Wang, Yinyan Wang, Zhaoshi Bao, Pei Yang, Xing Fan, Xing Liu, Zheng Zhao, Zheng Wang, Yiming Li, Zhiliang Wang, Guanzhang Li, Shengyu Fang, Lianwang Li, Yanwei Liu, Shuai Liu, Xia Shan, Yuqing Liu, Ruichao Chai, Huimin Hu, Jing Chen, Wei Yan, Jinquan Cai, Hongjun Wang, Lingchao Chen, Yuan Yang, Yu Wang, Lei Han, Qixue Wang

Summary: The joint guideline committee of Chinese Glioma Cooperative Group, Society for Neuro-Oncology of China, and Chinese Brain Cancer Association has updated the clinical practice guideline to provide recommendations for the diagnosis and management of diffuse gliomas. The guidelines focus on molecular and pathological diagnostics, as well as main treatment modalities including surgery, radiotherapy, and chemotherapy. Additionally, the guidelines integrate results from clinical trials of immune therapies and target therapies as future directions.

CANCER LETTERS (2021)

Article Oncology

A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma

Jixing Zhao, Shixue Yang, Xiaoteng Cui, Qixue Wang, Eryan Yang, Fei Tong, Biao Hong, Menglin Xiao, Lei Xin, Can Xu, Yanli Tan, Chunsheng Kang

Summary: Researchers have discovered a small-molecule inhibitor called EPIC-0412 that enhances the effectiveness of the chemotherapy drug TMZ in treating GBM. By disrupting DNA damage repair pathways and targeting MGMT, EPIC-0412 sensitizes GBM cells to TMZ and induces cell cycle arrest and apoptosis. The study also shows that EPIC-0412 epigenetically silences MGMT through specific pathways.

NEURO-ONCOLOGY (2023)

Editorial Material Oncology

Bridging deep sequencing to precision oncology in meningiomas

Xing Liu, Chunsheng Kang

NEURO-ONCOLOGY (2023)

Article Oncology

EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT

Lei Xin, Yanli Tan, Yuanxue Zhu, Xiaoteng Cui, Qixue Wang, Jixing Zhao, Shaohui Tian, Can Xu, Menglin Xiao, Biao Hong, Jianglong Xu, Xiaoye Yuan, Changsheng Wang, Chunsheng Kang, Chuan Fang

Summary: This study identified a potential small-molecule inhibitor, EPIC-0307, that selectively disrupted the PRADX-EZH2 interaction to upregulate expressions of tumor suppressor genes, thereby exerting its antitumor effects on GBM cells. EPIC-0307 treatment also increased the chemotherapeutic efficacy of TMZ by epigenetically downregulating DNA repair-associated genes and MGMT expression in GBM cells.

NEURO-ONCOLOGY (2023)

Review Oncology

Expert opinion on translational research for advanced glioblastoma treatment

Xiaoteng Cui, Yunfei Wang, Junhu Zhou, Qixue Wang, Chunsheng Kang

Summary: Malignant gliomas are difficult to diagnose and treat due to their infiltrative growth pattern, rapid progression, and poor prognosis. Temozolomide (TMZ) is the only first-line chemotherapeutic drug for malignant gliomas that can cross the blood-brain barrier, but some patients are insensitive to TMZ and can develop acquired resistance during treatment.

CANCER BIOLOGY & MEDICINE (2023)

Article Oncology

PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2

Kaikai Yi, Qi Zhan, Qixue Wang, Yanli Tan, Chuan Fang, Yunfei Wang, Junhu Zhou, Chao Yang, Yansheng Li, Chunsheng Kang

Summary: This study revealed that PTRF promotes GBM tumor proliferation and suppresses immune responses through a lipid remodeling pathway involving cPLA2. The overexpression of PTRF alters the metabolism of cells, affecting the growth and immune infiltration of GBM tumors. These findings highlight new therapeutic targets for GBM treatment.

NEURO-ONCOLOGY (2021)

Article Engineering, Multidisciplinary

The effect of umbrella-type branching on the blood circulation and tumor targeting of star-branched PLA-PMPC copolymer micelles

Long LiXia, Cheng LinJie, Hou JingJing, Wang LiMei, Wang Xu, He LiGang, Li SiDi, Zhao Jin, Hou Xin, Kang ChunSheng, Yuan XuBo

Summary: Increasing the branching degree of star-branched copolymers can improve the blood circulation and tumor-targeting effects of polymeric nanovehicles in vivo, allowing the payload to persist longer in the bloodstream.

SCIENCE CHINA-TECHNOLOGICAL SCIENCES (2021)

Article Medicine, Research & Experimental

Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein

Lin Wang, Junhu Zhou, Qixue Wang, Yunfei Wang, Chunsheng Kang

Summary: This study proposes a potential anti-SARS-CoV-2 strategy based on the CRISPR-Cas13a system, identifying a specific RNA segment of the spike protein and designing an efficient crRNA sequence for cleavage. It provides a rapid design pipeline for an antiviral tool against SARS-CoV-2 and introduces a novel approach for anti-virus study.

THERANOSTICS (2021)

Article Nanoscience & Nanotechnology

Multifunctional Nanomodulators Regulate Multiple Pathways To Enhance Antitumor Immunity

Yadan Zheng, Zhanzhan Zhang, Qi Liu, Yu Zhao, Chunxiong Zheng, Jialei Hao, Kaikai Yi, Ying Wang, Chun Wang, Xinzhi Zhao, Linqi Shi, Chunsheng Kang, Yang Liu

ACS APPLIED BIO MATERIALS (2020)

Article Medicine, Research & Experimental

LncRNA PRADX-mediated recruitment of PRC2/DDX5 complex suppresses UBXN1 expression and activates NF-KB activity, promoting tumorigenesis

Yansheng Li, Xing Liu, Xiaoteng Cui, Yanli Tan, Qixue Wang, Yunfei Wang, Can Xu, Chuan Fang, Chunsheng Kang

Summary: The study identified a novel cancer driver lncRNA named PRADX in glioblastoma and colon adenocarcinoma, which is highly expressed in tumor cells and tissues. Through various experiments, PRADX was found to interact with EZH2 protein, increase H3K27 trimethylation in the UBXN1 gene promoter, and promote NF-KB activity by suppressing UBXN1. Knockdown of PRADX inhibited tumor cell viability and growth both in vitro and in vivo, suggesting its potential as a therapeutic target for these cancers.

THERANOSTICS (2021)

No Data Available